De semillas a bioenergía: un camino de conversión para la valorización de semillas de ricino y jatrofa

The world’s energy matrix can be diversified with biodiesel from castor and jatropha oil. Hence, the objective of this study was to assess a conversion path for the valorization of castor and jatropha seeds. The results showed the maximum extraction of castor oil at 90 °C, 2 rpm, and 6 mm nozzle, achieving a yield of 36.97% and for jatropha oil at 100 °C, 1.5 rpm, and 10 mm nozzle, achieving a yield of 20.11%. The acid value and cloud point of castor and jatropha oil were 0.797 and 23.44 mg KOH/g, 10±1 °C and 12±0.55 °C, respectively; while the pour point was -3 °C for both. The acid value and cloud point for biodiesels ranged from 0.26-0.43 mg KOH/g, and -12.50-6.10 °C, respectively. The viscosity of oils and biodiesel ranged from 0.02-1.3 P. GC-MS indicated 66.38% of methyl ricinoleate in castor biodiesel and 31.64% of methyl oleate in jatropha biodiesel. The HHV for castor and jatropha biodiesel ranged from 32.37-40.25 MJ/kg.La matriz energética mundial puede diversificarse con biodiesel de ricino y de jatrofa. Por lo tanto, el objetivo de este trabajo fue evaluar la ruta de conversión de las semillas de ricino y jatrofa. Los resultados mostraron que la máxima extracción de aceite de ricino se dio a 90 °C, 2 rpm, y boquilla de 6 mm, alcanzando un rendimiento de 36,97% y para el aceite de jatrofa fue a 100 °C, 1,5 rpm, y boquilla de 10 mm, obteniendo un rendimiento de 20,11%. El índice de acidez y punto de nube del aceite de ricino y jatrofa fue de 0,797 y 23,44 mg de KOH/g, 10 ± 1 °C y 12 ± 0,55 °C, respectivamente, mientras que el punto de fluidez fue de -3 °C para ambos. El índice de acidez y el punto de nube del biodiésel de ricino y jatropha fueron 0,43 y 0,26 mg KOH/g, -12,50 °C y 6,10 °C, respectivamente. La viscosidad dinámica de los aceites y el biodiesel osciló entre 0,02 y 1,3 P. El análisis GC-MS indicó 66,38% de ricinoleato de metilo en biodiesel de higuerilla y 31,64% de oleato de metilo en biodiesel de jatrofa. El HHV para el biodiésel de ricino y jatrofa osciló entre 32,37 y 40,25 MJ/kg

The global retinoblastoma outcome study : a prospective, cluster-based analysis of 4064 patients from 149 countries

DATA SHARING : The study data will become available online once all analyses are complete.BACKGROUND : Retinoblastoma is the most common intraocular cancer worldwide. There is some evidence to suggest that major differences exist in treatment outcomes for children with retinoblastoma from different regions, but these differences have not been assessed on a global scale. We aimed to report 3-year outcomes for children with retinoblastoma globally and to investigate factors associated with survival. METHODS : We did a prospective cluster-based analysis of treatment-naive patients with retinoblastoma who were diagnosed between Jan 1, 2017, and Dec 31, 2017, then treated and followed up for 3 years. Patients were recruited from 260 specialised treatment centres worldwide. Data were obtained from participating centres on primary and additional treatments, duration of follow-up, metastasis, eye globe salvage, and survival outcome. We analysed time to death and time to enucleation with Cox regression models. FINDINGS : The cohort included 4064 children from 149 countries. The median age at diagnosis was 23·2 months (IQR 11·0–36·5). Extraocular tumour spread (cT4 of the cTNMH classification) at diagnosis was reported in five (0·8%) of 636 children from high-income countries, 55 (5·4%) of 1027 children from upper-middle-income countries, 342 (19·7%) of 1738 children from lower-middle-income countries, and 196 (42·9%) of 457 children from low-income countries. Enucleation surgery was available for all children and intravenous chemotherapy was available for 4014 (98·8%) of 4064 children. The 3-year survival rate was 99·5% (95% CI 98·8–100·0) for children from high-income countries, 91·2% (89·5–93·0) for children from upper-middle-income countries, 80·3% (78·3–82·3) for children from lower-middle-income countries, and 57·3% (52·1-63·0) for children from low-income countries. On analysis, independent factors for worse survival were residence in low-income countries compared to high-income countries (hazard ratio 16·67; 95% CI 4·76–50·00), cT4 advanced tumour compared to cT1 (8·98; 4·44–18·18), and older age at diagnosis in children up to 3 years (1·38 per year; 1·23–1·56). For children aged 3–7 years, the mortality risk decreased slightly (p=0·0104 for the change in slope). INTERPRETATION : This study, estimated to include approximately half of all new retinoblastoma cases worldwide in 2017, shows profound inequity in survival of children depending on the national income level of their country of residence. In high-income countries, death from retinoblastoma is rare, whereas in low-income countries estimated 3-year survival is just over 50%. Although essential treatments are available in nearly all countries, early diagnosis and treatment in low-income countries are key to improving survival outcomes.The Queen Elizabeth Diamond Jubilee Trust and the Wellcome Trust.https://www.thelancet.com/journals/langlo/homeam2023Paediatrics and Child Healt

International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module

•We report INICC device-associated module data of 50 countries from 2010-2015.•We collected prospective data from 861,284 patients in 703 ICUs for 3,506,562 days.•DA-HAI rates and bacterial resistance were higher in the INICC ICUs than in CDC-NHSN's.•Device utilization ratio in the INICC ICUs was similar to CDC-NHSN's. Background: We report the results of International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2010-December 2015 in 703 intensive care units (ICUs) in Latin America, Europe, Eastern Mediterranean, Southeast Asia, and Western Pacific. Methods: During the 6-year study period, using Centers for Disease Control and Prevention National Healthcare Safety Network (CDC-NHSN) definitions for device-associated health care-associated infection (DA-HAI), we collected prospective data from 861,284 patients hospitalized in INICC hospital ICUs for an aggregate of 3,506,562 days. Results: Although device use in INICC ICUs was similar to that reported from CDC-NHSN ICUs, DA-HAI rates were higher in the INICC ICUs: in the INICC medical-surgical ICUs, the pooled rate of central line-associated bloodstream infection, 4.1 per 1,000 central line-days, was nearly 5-fold higher than the 0.8 per 1,000 central line-days reported from comparable US ICUs, the overall rate of ventilator-associated pneumonia was also higher, 13.1 versus 0.9 per 1,000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 5.07 versus 1.7 per 1,000 catheter-days. From blood cultures samples, frequencies of resistance of Pseudomonas isolates to amikacin (29.87% vs 10%) and to imipenem (44.3% vs 26.1%), and of Klebsiella pneumoniae isolates to ceftazidime (73.2% vs 28.8%) and to imipenem (43.27% vs 12.8%) were also higher in the INICC ICUs compared with CDC-NHSN ICUs. Conclusions: Although DA-HAIs in INICC ICU patients continue to be higher than the rates reported in CDC-NSHN ICUs representing the developed world, we have observed a significant trend toward the reduction of DA-HAI rates in INICC ICUs as shown in each international report. It is INICC's main goal to continue facilitating education, training, and basic and cost-effective tools and resources, such as standardized forms and an online platform, to tackle this problem effectively and systematically